testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest
RD
testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest testtesttesttesttesttesttesttest
Sign in to join the discussion.
FDR (Benjamini-Hochberg) is widely accepted and preferable to Bonferroni when you have many tests and limited power. The key is to be explicit about which correction you used and why.
On replication: No independent cohort is a genuine limitation but not a dealbreaker for rare disease research, where cohort availability is a known constraint. Many high-quality papers acknowledge this and still get published in good journals. Frame it as future work.
Power analysis: Yes, report it. Showing you are aware of the limitation is better than not mentioning it.
Seconding the recommendation for Zotero. Game changer for managing references across multiple projects.
I am in a very similar situation. Would you be willing to share the outline of your PMRF proposal? Not the content.just the section headings and approximate word allocation.
This is a known issue with XLM-R on code-mixed data. The MuRIL preprint has a section specifically comparing these.
I found that writing a paper abstract first (before the paper) and then reverse-engineering the paper from the abstract helped with clarity enormously.
Could you clarify what you mean by results-blind review? I have heard of it but never understood how it works in practice. Wouldn't reviewers need to see results to evaluate whether the methodology is sound?
For longitudinal data with missing values, mixed-effects models handle this more gracefully than imputation in most cases.
I'd push back slightly on the idea that industry collaboration is universally beneficial for academic research. The incentive misalignment is real.
Industry partners want deliverables on a schedule. Academic research is often exploratory and unpredictable. When the two clash, it is usually the researcher who has to compromise.either by rushing results, constraining publication, or steering away from results that are inconvenient for the sponsor.
This doesn't mean industry collaboration is bad. But the terms matter enormously. IP rights, publication rights, and the ability to pursue negative results should be negotiated upfront and protected in writing.
Could you clarify what you mean by results-blind review? I have heard of it but never understood how it works in practice. Wouldn't reviewers need to see results to evaluate whether the methodology is sound?
Thank you for this detailed answer! A quick follow-up: when you mention cosine learning rate with warm-up, are you warming up the LoRA parameters specifically or the entire model including the frozen backbone?
Open access is the right direction but the APCs are prohibitively expensive for many Indian researchers without institutional funding.
I have a slightly different take from my experience in industry research. The reproducibility crisis is real but unevenly distributed. Fields with strong engineering culture (computational biology, ML with benchmarks) have actually improved significantly in the last 5 years. The bigger problem is in fields where data sharing is structurally difficult.clinical medicine, behavioral economics.
The ML community's move toward open code and reproducibility checklists has been genuinely effective.
Flower (flwr) is the most actively maintained and research-friendly federated learning framework right now. My group has been using it for 18 months on a healthcare project with 4 hospital sites.
Strengths:
For non-IID data specifically, look at the FedProx strategy.it handles heterogeneous data distributions much better than FedAvg.
Overleaf + GitHub integration is underrated. You get version control and collaboration in one place.
Thank you for this detailed answer! A quick follow-up: when you mention cosine learning rate with warm-up, are you warming up the LoRA parameters specifically or the entire model including the frozen backbone?
I am in a very similar situation. Would you be willing to share the outline of your PMRF proposal? Not the content.just the section headings and approximate word allocation.
Highly recommend checking out the PMRF portal for the actual numbers.they update the stipend structure annually.
For longitudinal data with missing values, mixed-effects models handle this more gracefully than imputation in most cases.
Really appreciate you taking the time to write this out in detail. This is going straight into my research notes.
Marking this as the accepted answer. Incredibly helpful and specific. Really appreciate you taking the time.